Transform your Head & Neck Cancer Drug Development Research
Champions' Head & Neck Cancer in vivo screen is a premier in vivo drug screening platform developed to support the discovery of breakthrough cancer therapies targeting an array of head & neck cancers. Featuring one of the largest banks of head & neck cancers in the industry, available with 60 Patient-Derived Xenograft (PDX) models retaining key clinical and molecular cancer characteristics, mutation profiles, and many pretreated models with the latest generation cancer therapies, providing a screening platform to assess the therapeutic potential and efficacy of your drug candidates.
Clinically Relevant Models
Living & diverse bank of 60 clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions' leading Head & Neck Cancer In Vivo Screen showcases 60 PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Includes models pretreated with advanced cancer therapies and those resistant to targeted treatments and the latest immunotherapies targeting CDK4, PI3K, and EGFR.
-
Features models retaining key mutation profiles and clinical cancer characteristics, such as models that are HPV16+ and/or HPV18+.
-
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
-
Terminal tumor collections for target validation is available upon request (Snap Frozen/FFPE)
-
Flow Cytometry & IHC data available upon request
-
No minimum to enroll & 50% off a Standard of Care Agent arm (selected by Champions)
PDX In Vivo Drug Responses Correlate to Clinical Outcomes
Figure 1: A correlation between the results obtained from the PDX model CTG-2344, developed from a metastatic neck tumor, and the patient's clinical responses.
Head & Neck Cancer PDX In Vivo Drug Responses
Figure 2: In vivo waterfall plots of head & neck cancer PDX models included in the screen show individual patterns of drug responses by PDX models to Cisplatin and Cetuximab.